{"schema":"sb.node.v1","id":"sb:e/dbbc0c48c528da248f2dd840","kind":"entity","label":{"text":"media relations","locale":"en"},"identity":{"anchor":"label:en:media relations","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T19:01:08.010113+00:00","snapshot":"deploy 87f2a55dbf39377b6f8497fa6fc2c6ae77d8a6f8"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":129,"separatePublishers":24,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.302: about 70% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto"],"activeDays":30,"assertions":{"regulatory-approval":15,"launch-release":7,"election":7,"sanction-trade":3,"meeting-visit":3,"sports-outcome":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/331e82e66c293bec85e9a0bd","kind":"observation","label":"Insurance Journal · 2026-10-08 · Two Past Hurricanes, OIR Data Give Idea of What to Expect From Isaias in Florida","url":"https://www.insurancejournal.com/news/southeast/2026/10/08/888368.htm"},{"id":"sb:o/6a66ee2ea6027abb5402c9b9","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-08 · Ribo Files EU Trial Application for INHBE-Targeting Obesity Drug RBD3133","url":"https://www.clinicaltrialvanguard.com/news/ribo-files-eu-trial-application-for-inhbe-targeting-obesity-drug-rbd3133/"},{"id":"sb:o/6ce97a3f017efe882a17e818","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-08 · Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials","url":"https://www.clinicaltrialvanguard.com/news/remibrutinib-reduces-relapse-rates-versus-teriflunomide-in-phase-3-ms-trials/"},{"id":"sb:o/133be0377b4a9dd48feea03e","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-08 · Jupiter Neurosciences Doses First Parkinson’s Patient in JOTROL Phase 2a Trial","url":"https://www.clinicaltrialvanguard.com/news/jupiter-neurosciences-doses-first-parkinsons-patient-in-jotrol-phase-2a-trial/"},{"id":"sb:o/ad249ba6f10b525ae8d8aebd","kind":"observation","label":"Financial Post · 2026-10-08 · General Fusion, UKAEA Announce Magnetized Target Fusion Milestone","url":"https://financialpost.com/globe-newswire/general-fusion-ukaea-announce-magnetized-target-fusion-milestone"},{"id":"sb:o/e456982ea512f133e2f71382","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-08 · FDA approves Rhapsido (remibrutinib) for symptomatic dermographism","url":"https://www.clinicaltrialvanguard.com/news/fda-approves-rhapsido-remibrutinib-for-symptomatic-dermographism/"},{"id":"sb:o/506afd002bedc7497b432fc5","kind":"observation","label":"PR Newswire · 2026-10-08 · Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upcoming October Conferences","url":"https://www.prnewswire.com/news-releases/consano-bio-to-highlight-c-1101-its-potential-first-in-class-disease-modifying-therapeutic-for-chronic-sciatica-at-upcoming-october-conferences-302901769.html"},{"id":"sb:o/583c43675612d1a38978ec4e","kind":"observation","label":"African Export-Import Bank · 2026-10-08 · Afreximbank welcomes launch of Africa Credit Rating Agency as an important step in strengthening Africa’s financial architecture","url":"https://www.afreximbank.com/afreximbank-welcomes-launch-of-africa-credit-rating-agency-as-an-important-step-in-strengthening-africas-financial-architecture/"},{"id":"sb:o/30ded5040173300f027e700e","kind":"observation","label":"PR Newswire · 2026-10-07 · Tech Beats Tariffs: Global Trade Growth Accelerates and Globalization Sets New Record","url":"https://www.prnewswire.com/news-releases/tech-beats-tariffs-global-trade-growth-accelerates-and-globalization-sets-new-record-302900608.html"},{"id":"sb:o/b230447b8a4ff7d1de65a853","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-07 · Rezdiffra Shows Consistent Efficacy Across MASH Genetic Risk Variants","url":"https://www.clinicaltrialvanguard.com/news/rezdiffra-shows-consistent-efficacy-across-mash-genetic-risk-variants/"}],"cursor":"c1.eyJpZCI6InNiOmUvZGJiYzBjNDhjNTI4ZGEyNDhmMmRkODQwIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDE5OjAxOjA4LjAxMDExMyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with clinical trial (80 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/16b1c89944e7fe75a963bb27"},{"kind":"relation","label":"co-mentioned with vanguard (79 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4b2c9073c0bf5714f97689b6"},{"kind":"relation","label":"co-mentioned with fda (57 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7f4b5e98767d18f960800ed7"},{"kind":"relation","label":"co-mentioned with studie (20 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3797d864b27a879322f84ad6"},{"kind":"relation","label":"co-mentioned with size (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5af230fbdc5b79cd56ade224"},{"kind":"relation","label":"co-mentioned with ai (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b8f57ad5698b960f671434b4"},{"kind":"relation","label":"co-mentioned with united states (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/24a3204907d13cd5ed6c4ac5"},{"kind":"relation","label":"co-mentioned with china (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/de12c18d685813de09bc68d6"},{"kind":"relation","label":"co-mentioned with prnewswire (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0519e71d1025606370d23c21"},{"kind":"relation","label":"co-mentioned with industrie (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ffa601027818228d5e773ad6"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/dbbc0c48c528da248f2dd840","mcp":"traverse {\"id\":\"sb:e/dbbc0c48c528da248f2dd840\"}","page":"/entity/media-relations/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/dbbc0c48c528da248f2dd840\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/dbbc0c48c528da248f2dd840\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/dbbc0c48c528da248f2dd840\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/dbbc0c48c528da248f2dd840\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}